Analystreport

Reata Pharmaceuticals, Inc. (NASDAQ: RETA) had its "buy" rating re-affirmed by analysts at Robert W. Baird. They now have a $47.00 price target on the stock.

Reata Pharmaceuticals, Inc. - Class A  (RETA) 
Last reata pharmaceuticals, inc. - class a earnings: 2/19 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.reatapharma.com